Detailed Narrative
Gagillapur Facility FDA Remediation Update
Granules India's Gagillapur finished dosage facility received a US FDA warning letter on February 26, 2025, following an August 2024 inspection with six Form 483 observations. While commercial product supply remains unaffected, the warning letter may temporarily impact FDA review of pending product submissions. Remediation efforts, guided by three consulting firms, have led to a slowdown in operations, which impacted Q4 output and is expected to continue for another one to two quarters. The company has tested over 1,200 batches and 2,600 swab/rinse samples, all within acceptable limits, and expects remediation expenses of approximately ₹60 crores for FY25, continuing into Q1 and Q2 FY26.
Strategic Acquisition of Senn Chemicals and Peptide Foray
Granules has strategically acquired Senn Chemicals, a Swiss-based CDMO, marking its entry into the high-growth peptide therapeutic space, including GLP-1 receptor anti-agonists. Senn Chemicals currently generates roughly CHF20 million in annual sales and operates at a breakeven or slight loss, which is expected to continue for the next 1-3 quarters. Granules plans significant CAPEX in Switzerland and for a new peptide R&D and manufacturing facility in Hyderabad, aiming to leverage Senn's capabilities for both CDMO business and Granules' own GLP-1 API and formulation development.
Genome Valley Formulation Facility Progress
The new formulation facility at Genome Valley under Granules Life Sciences is progressing well. Phase-1, with a capacity of 2.5 billion dosages, has been commissioned, and commercial dispatches of monograph products are ongoing. Phase-2, adding an additional 7.5 billion dose capacity, has been commissioned in Q4 FY25 and is expected to be fully operational by next month. The company anticipates 40-50% capacity utilization by the end of FY26 and close to 90% by the end of FY27, pending FDA and European agency inspections expected in Q2 FY26.
R&D Investment and Portfolio Expansion
Granules' R&D spend increased by 20% to ₹2,377 million in FY25, demonstrating a strong commitment to portfolio expansion. The company filed three US ANDAs and six European dossiers in Q4 FY25, bringing the total to 127 dossiers across regions. Significant progress has been made in the ADHD portfolio, with 10 products in the pipeline, including the launch of lisdexamfetamine capsules and chewable tablets in Q4 FY25. The oncology pipeline also includes around 10 products under development, with the first US ANDA and European filing submitted in Q4 FY25, expected to yield revenues from FY28 onwards.
Financial Performance and Margin Improvement
Q4 FY25 revenue grew 2% YoY to ₹11,974 million, while full-year FY25 revenue was ₹44,816 million. Gross margin significantly improved to 63.4% in Q4 FY25, up 333 basis points YoY, primarily due to a strategic shift towards higher-margin formulation products. EBITDA for Q4 FY25 was ₹2,524 million (21.1% margin), a slight YoY decline but an 83 basis point QoQ improvement. Full-year EBITDA grew 10% to ₹9,452 million, despite increased professional expenses for FDA remediation and higher R&D costs. Net debt reduced to ₹7,061 million in Q4 FY25 from ₹8,289 million in Q3 FY25.
API/PFI Strategy and Geographical Mix
Granules is strategically reducing its reliance on API sales, with the API/PFI segment contributing less than 25% of current revenue and expected to remain in that range going forward⏳. The focus is on vertical integration, converting most APIs into PFIs and FDs for in-house consumption, especially for paracetamol where global overcapacity exists. North America remains the biggest growth driver, accounting for 79% of Q4 FY25 revenues. The company is also expanding filings in Europe (11 filings in FY25) and other ROW markets to diversify its geographical revenue mix, although the US market will continue to be a primary focus due to its size.